ARID4B and breast carcinoma: In all cases, the mutations produced were heterozygous (partial knockout), which seems more similar to the genomic context in breast cancer patients in comparison to previous experiments performed in ARID4B that used RNA silencing or knockouts deleting both alleles and cell lines other than breast-derived [17,19,42].